| scholarly article | Q13442814 |
| P50 | author | Razelle Kurzrock | Q56614941 |
| P2093 | author name string | Sadakatsu Ikeda | |
| Gregory M Heestand | |||
| Paul T Fanta | |||
| Paul Riviere | |||
| Joel Baumgartner | |||
| P2860 | cites work | KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 |
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 | ||
| Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
| Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials | Q30783484 | ||
| Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms | Q33756991 | ||
| Unique molecular landscapes in cancer: implications for individualized, curated drug combinations | Q34938532 | ||
| Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer | Q35615320 | ||
| Genomic analysis of circulating cell-free DNA infers breast cancer dormancy | Q35694373 | ||
| Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA | Q35810461 | ||
| Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology | Q36544915 | ||
| Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay | Q36962764 | ||
| Genetic and phenotypic diversity in breast tumor metastases | Q37659374 | ||
| Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution | Q38257912 | ||
| Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. | Q38390966 | ||
| Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer | Q40149888 | ||
| Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients | Q40374512 | ||
| BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer | Q40823445 | ||
| Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes | Q43207016 | ||
| Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. | Q45954561 | ||
| Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers | Q50539670 | ||
| Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking Precision Medicine. | Q51275924 | ||
| Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. | Q51752412 | ||
| Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. | Q54169673 | ||
| Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients | Q57280718 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 297-305 | |
| P577 | publication date | 2017-11-13 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. | |
| P478 | volume | 17 |
| Q55310646 | A Review of Circulating Tumor DNA in Hepatobiliary Malignancies. |
| Q57801967 | Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction and Gastric Adenocarcinoma |
| Q91809618 | Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer Patients |
| Q64949380 | Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. |
| Q92486902 | Feasibility of circulating tumor DNA testing in hepatocellular carcinoma |
| Q64239421 | Revisiting Epidermal Growth Factor Receptor () Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies |
Search more.